Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

J&J Recalls 667,632 Sudafed Packages Over Labeling Error

Feb. 24 (Bloomberg) -- Johnson & Johnson, the world’s largest maker of consumer health products, said it is recalling nine lots of extended-release Sudafed tablets in the U.S. because of a typographical error in the directions on the label.

The cold medicine’s label includes an extra “not” when directing patients “do not not divide, crush, chew, or dissolve the tablet,” J&J said in a notice today on its website. The New Brunswick, New Jersey-based company said the recall affects 667,632 products and hasn’t been linked to any injuries.

Recalls cost J&J $900 million in sales last year, including dozens of over-the-counter medicines found to be contaminated or incorrectly labeled. So far this month, the company and its subsidiaries have withdrawn defective Simponi injectable pens for arthritis, vials of discolored Dermabond skin adhesive and possibly cracked syringes of Invega Sustenna for schizophrenia.

Today’s recall affects Sudafed 24-Hour sold in packages of 10 tablets at the wholesale level, J&J said. Consumers aren’t required to take any action and can use the medicine by following the correct directions on the blister packaging, the company said.

To contact the reporter on this story: Catherine Larkin in Washington at

To contact the editor responsible for this story: Adriel Bettelheim at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.